Source: Investing.com

Gyre Therapeutics: Gyre Therapeutics offers weak 2025 revenue guidance By Investing.com

Gyre Therapeutics offers weak 2025 revenue guidance

Read full article »
Gyre Therapeutics's Competitors | Gyre Therapeutics's News | Gyre Therapeutics's Financials
Stay up-to-date with the latest news on Gyre Therapeutics
Annual Revenue
$100-500M
Employees
500-1.0K
Charles Wu's photo - CEO of Gyre Therapeutics

CEO

Charles Wu

CEO Approval Rating

82/100

Read more
Stay up-to-date with the latest news on Gyre Therapeutics